Abstract |
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO). The two treatment periods were separated by 6 months. Both treatments resulted in marked clinical improvement. In response to CPA treatment, basal plasma gonadotropin, estradiol, estrone, testosterone and androstenedione levels significantly decreased. In response to D-Trp6 LHRH, both basal and stimulated gonadotropin levels were completely suppressed after 3 weeks of treatment. After initial elevation on day 2, plasma ovarian steroid levels fell into the castrate range, without any change in dehydroepiandrosterone sulfate levels. Urinary 3 alpha-androstanediol excretion decreased significantly. In patients with PCO, LHRH-A induced more complete gonadotropin inhibition than did CPA. However, following cessation of either therapy, the disease rapidly recurred.
|
Authors | G Schaison, B Couzinet |
Journal | Hormone research
(Horm Res)
Vol. 28
Issue 2-4
Pg. 169-74
( 1987)
ISSN: 0301-0163 [Print] Switzerland |
PMID | 2969860
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Androgens
- Delayed-Action Preparations
- Luteolytic Agents
- Triptorelin Pamoate
- Estrone
- Gonadotropin-Releasing Hormone
- Cyproterone Acetate
- Estradiol
- Luteinizing Hormone
- Cyproterone
|
Topics |
- Adult
- Androgens
(blood)
- Clinical Trials as Topic
- Cyproterone
(analogs & derivatives, therapeutic use)
- Cyproterone Acetate
- Delayed-Action Preparations
- Estradiol
(blood)
- Estrone
(blood)
- Female
- Gonadotropin-Releasing Hormone
(analogs & derivatives, therapeutic use)
- Humans
- Luteinizing Hormone
(metabolism)
- Luteolytic Agents
(therapeutic use)
- Polycystic Ovary Syndrome
(drug therapy)
- Random Allocation
- Triptorelin Pamoate
|